316 related articles for article (PubMed ID: 26198928)
1. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
Toghianifar N; Ashtari F; Zarkesh-Esfahani SH; Mansourian M
J Neuroimmunol; 2015 Aug; 285():125-8. PubMed ID: 26198928
[TBL] [Abstract][Full Text] [Related]
2. Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
Ashtari F; Toghianifar N; Zarkesh-Esfahani SH; Mansourian M
Neuroimmunomodulation; 2015; 22(6):400-4. PubMed ID: 26401986
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.
Røsjø E; Steffensen LH; Jørgensen L; Lindstrøm JC; Šaltytė Benth J; Michelsen AE; Aukrust P; Ueland T; Kampman MT; Torkildsen Ø; Holmøy T
J Neurol; 2015 Dec; 262(12):2713-21. PubMed ID: 26429571
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.
Smolders J; Hupperts R; Barkhof F; Grimaldi LM; Holmoy T; Killestein J; Rieckmann P; Schluep M; Vieth R; Hostalek U; Ghazi-Visser L; Beelke M;
J Neurol Sci; 2011 Dec; 311(1-2):44-9. PubMed ID: 21620416
[TBL] [Abstract][Full Text] [Related]
5. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
Ashtari F; Toghianifar N; Zarkesh-Esfahani SH; Mansourian M
Neurol Res; 2016 Oct; 38(10):888-92. PubMed ID: 27597724
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties.
Golan D; Halhal B; Glass-Marmor L; Staun-Ram E; Rozenberg O; Lavi I; Dishon S; Barak M; Ish-Shalom S; Miller A
BMC Neurol; 2013 Jun; 13():60. PubMed ID: 23767916
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of daily high-dose vitamin D
Hupperts R; Smolders J; Vieth R; Holmøy T; Marhardt K; Schluep M; Killestein J; Barkhof F; Beelke M; Grimaldi LME;
Neurology; 2019 Nov; 93(20):e1906-e1916. PubMed ID: 31594857
[TBL] [Abstract][Full Text] [Related]
8. Immune regulatory effects of high dose vitamin D
Muris AH; Smolders J; Rolf L; Thewissen M; Hupperts R; Damoiseaux J;
J Neuroimmunol; 2016 Nov; 300():47-56. PubMed ID: 27806875
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D
Smolders J; Mimpen M; Oechtering J; Damoiseaux J; van den Ouweland J; Hupperts R; Kuhle J
Acta Neurol Scand; 2020 Jan; 141(1):77-80. PubMed ID: 31657006
[TBL] [Abstract][Full Text] [Related]
11. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
Bhargava P; Cassard S; Steele SU; Azevedo C; Pelletier D; Sugar EA; Waubant E; Mowry EM
Contemp Clin Trials; 2014 Nov; 39(2):288-93. PubMed ID: 25311447
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta.
Åivo J; Hänninen A; Ilonen J; Soilu-Hänninen M
J Neuroimmunol; 2015 Mar; 280():12-5. PubMed ID: 25773149
[TBL] [Abstract][Full Text] [Related]
13. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial.
Sanoobar M; Eghtesadi S; Azimi A; Khalili M; Khodadadi B; Jazayeri S; Gohari MR; Aryaeian N
Nutr Neurosci; 2015 May; 18(4):169-76. PubMed ID: 24621064
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
[TBL] [Abstract][Full Text] [Related]
15. Effect of high-dose vitamin D
Røsjø E; Lossius A; Abdelmagid N; Lindstrøm JC; Kampman MT; Jørgensen L; Sundström P; Olsson T; Steffensen LH; Torkildsen Ø; Holmøy T
Mult Scler; 2017 Mar; 23(3):395-402. PubMed ID: 27325604
[TBL] [Abstract][Full Text] [Related]
16. High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.
Holmøy T; Lindstrøm JC; Eriksen EF; Steffensen LH; Kampman MT
BMC Neurol; 2017 Apr; 17(1):67. PubMed ID: 28376767
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
Bălaşa R; Bajko Z; Huţanu A
Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
[TBL] [Abstract][Full Text] [Related]
19. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Derakhshandi H; Etemadifar M; Feizi A; Abtahi SH; Minagar A; Abtahi MA; Abtahi ZA; Dehghani A; Sajjadi S; Tabrizi N
Acta Neurol Belg; 2013 Sep; 113(3):257-63. PubMed ID: 23250818
[TBL] [Abstract][Full Text] [Related]
20. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).
Camu W; Lehert P; Pierrot-Deseilligny C; Hautecoeur P; Besserve A; Jean Deleglise AS; Payet M; Thouvenot E; Souberbielle JC
Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):. PubMed ID: 31454777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
